Identification of the Promoter of Human Carbonyl Reductase 3 (CBR3) and Impact of Common Promoter Polymorphisms on Hepatic CBR3 mRNA Expression

[1] Matsunaga T(2006)Multiplicity of mammalian reductases for xenobiotic carbonyl compounds Drug Metab Pharmacokinet 21 1-18

[2] Shintani S(2004)Human carbonyl reduction pathways and a strategy for their study in vitro Drug Metab Rev 36 335-61

[3] Hara A(2000)Carbonyl reductase Chem Biol Interact 129 21-40

[4] Rosemond MJ(2004)Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185-229

[5] Walsh JS(2008)Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity Pharmacogenet Genomics 18 623-31

[6] Forrest GL(2008)CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients Cancer Sci 99 2045-54

[7] Gonzalez B(2008)Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer Cancer 112 2789-95

[8] Minotti G(1998)Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2 Genomics 52 95-100

[9] Menna P(2006)Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites Toxicol Lett 164 249-58

[10] Salvatorelli E(2009)Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors Drug Metab Dispos 37 400-7

[1] Matsunaga T(2006)Multiplicity of mammalian reductases for xenobiotic carbonyl compounds Drug Metab Pharmacokinet 21 1-18

[2] Shintani S(2004)Human carbonyl reduction pathways and a strategy for their study in vitro Drug Metab Rev 36 335-61

[3] Hara A(2000)Carbonyl reductase Chem Biol Interact 129 21-40

[4] Rosemond MJ(2004)Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185-229

[5] Walsh JS(2008)Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity Pharmacogenet Genomics 18 623-31

[6] Forrest GL(2008)CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients Cancer Sci 99 2045-54

[7] Gonzalez B(2008)Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer Cancer 112 2789-95

[8] Minotti G(1998)Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2 Genomics 52 95-100

[9] Menna P(2006)Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites Toxicol Lett 164 249-58

[10] Salvatorelli E(2009)Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors Drug Metab Dispos 37 400-7